Immunotherapy and chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell carcinoma (a type of esophageal cancer) that can be removed with surgery.
- Your cancer is at stage II, III, or IVA (meaning it hasn't spread to distant organs).
- You are generally able to care for yourself (ECOG score 0 or 1).
- You have not had other cancers in the last 5 years (except certain non-melanoma skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This study tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (sintilimab) given before surgery for esophageal cancer. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (interferon gamma and camrelizumab) given before surgery for a certain type of esophageal cancer. It aims to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.